Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ryan Ramanujam

Showing results (21-30 of 30) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 30 results.
Multiple Sclerosis (Houndmills, Basingstoke, England)|December 2, 2020
Accurate classification of secondary progression in multiple sclerosis using a decision treeRyan Ramanujam, Feng Zhu, Katharina Fink, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|February 4, 2017
Age Related Multiple Sclerosis Severity Score: Disability ranked by ageAli Manouchehrinia, Helga Westerlind, Elaine Kingwell, et al.
Neurology|November 2, 2014
Initial lymphocyte count and low BMI may affect fingolimod-induced lymphopeniaClemens Warnke, Thomas Dehmel, Ryan Ramanujam, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|March 7, 2013
Changes to anti-JCV antibody levels in a Swedish national MS cohortClemens Warnke, Ryan Ramanujam, Tatiana Plavina, et al.
European Journal of Human Genetics : EJHG|August 28, 2014
Identity-by-descent mapping in a Scandinavian multiple sclerosis cohortHelga Westerlind, Kerstin Imrell, Ryan Ramanujam, et al.
Therapeutic Advances in Neurological Disorders|September 29, 2023
The impact of healthcare systems on the clinical diagnosis and disease-modifying treatment usage in relapse-onset multiple sclerosis: a real-world perspective in five registries across EuropeRichard Nicholas, Jeff Rodgers, James Witts, et al.
Multiple Sclerosis Journal - Experimental, Translational and Clinical|February 23, 2023
Proportion and characteristics of secondary progressive multiple sclerosis in five European registries using objective classifiersLars Forsberg, Tim Spelman, Pernilla Klyve, et al.
Plos One|November 3, 2016
Occurrence of Anti-Drug Antibodies against Interferon-Beta and Natalizumab in Multiple Sclerosis: A Collaborative Cohort AnalysisDelphine Bachelet, Signe Hässler, Cyprien Mbogning, et al.
Plos One|February 8, 2017
Clinical practice of analysis of anti-drug antibodies against interferon beta and natalizumab in multiple sclerosis patients in Europe: A descriptive study of test resultsJenny Link, Ryan Ramanujam, Michael Auer, et al.
Journal of Neuroimmunology|November 18, 2018
Detection and kinetics of persistent neutralizing anti-interferon-beta antibodies in patients with multiple sclerosis. Results from the ABIRISK prospective cohort studyPoul Erik H Jensen, Clemens Warnke, Kathleen Ingenhoven, et al.
Pageof 3

Showing results (21-30 of 30) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 30 results.
Multiple Sclerosis (Houndmills, Basingstoke, England)|December 2, 2020
Accurate classification of secondary progression in multiple sclerosis using a decision treeRyan Ramanujam, Feng Zhu, Katharina Fink, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|February 4, 2017
Age Related Multiple Sclerosis Severity Score: Disability ranked by ageAli Manouchehrinia, Helga Westerlind, Elaine Kingwell, et al.
Neurology|November 2, 2014
Initial lymphocyte count and low BMI may affect fingolimod-induced lymphopeniaClemens Warnke, Thomas Dehmel, Ryan Ramanujam, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|March 7, 2013
Changes to anti-JCV antibody levels in a Swedish national MS cohortClemens Warnke, Ryan Ramanujam, Tatiana Plavina, et al.
European Journal of Human Genetics : EJHG|August 28, 2014
Identity-by-descent mapping in a Scandinavian multiple sclerosis cohortHelga Westerlind, Kerstin Imrell, Ryan Ramanujam, et al.
Therapeutic Advances in Neurological Disorders|September 29, 2023
The impact of healthcare systems on the clinical diagnosis and disease-modifying treatment usage in relapse-onset multiple sclerosis: a real-world perspective in five registries across EuropeRichard Nicholas, Jeff Rodgers, James Witts, et al.
Multiple Sclerosis Journal - Experimental, Translational and Clinical|February 23, 2023
Proportion and characteristics of secondary progressive multiple sclerosis in five European registries using objective classifiersLars Forsberg, Tim Spelman, Pernilla Klyve, et al.
Plos One|November 3, 2016
Occurrence of Anti-Drug Antibodies against Interferon-Beta and Natalizumab in Multiple Sclerosis: A Collaborative Cohort AnalysisDelphine Bachelet, Signe Hässler, Cyprien Mbogning, et al.
Plos One|February 8, 2017
Clinical practice of analysis of anti-drug antibodies against interferon beta and natalizumab in multiple sclerosis patients in Europe: A descriptive study of test resultsJenny Link, Ryan Ramanujam, Michael Auer, et al.
Journal of Neuroimmunology|November 18, 2018
Detection and kinetics of persistent neutralizing anti-interferon-beta antibodies in patients with multiple sclerosis. Results from the ABIRISK prospective cohort studyPoul Erik H Jensen, Clemens Warnke, Kathleen Ingenhoven, et al.
Pageof 3